Loading…
Chinese biopharma company making biologics including erythropoietin (EPO) and other injectable drugs, parent of Sunshine Guojian.
Chinese biopharma company making biologics including erythropoietin (EPO) and other injectable drugs, parent of Sunshine Guojian.
Sells legacy biologics such as TPIAO, a platelet-boosting drug, and EPO through hospitals in China, and these long-established products carry current earnings. Out-licensing is the newer line: in 2025 it gave Pfizer rights outside China to a cancer antibody drug in exchange for upfront and milestone payments.
In one line: A Chinese Amgen-scale biologics maker.
Moat: narrow (scale, IP / patents, distribution). Established hospital distribution for legacy biologics plus a growing biosimilar/innovative pipeline via its subsidiary.
Headquarters: Shenyang, China · Founded: 1993 · Employees: 6,109
Size 3SBio (1530.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $4.92B, the 256th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$15.18 on 6 Nov 2026.
Performance Over six months the shares fell 33.8%, against +2.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 101.7% over the last twelve months (peer median +3.6%); the operating margin is 60.6% (peer median -23.4%).
Valuation It trades at 13.7× forward earnings against a peer median of 37.3× (cheapest of 7).
Capital Return on invested capital runs 39.6 points above its cost of capital (9.0% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$19.8B | HK$19.2B | HK$9.88B | HK$8.64B | HK$7.98B |
| Revenue growth | — | +94% | +14% | +8% | — |
| Gross profit | HK$18.2B | HK$17.7B | HK$8.49B | HK$7.34B | HK$6.60B |
| EBITDA | HK$12.6B | HK$12.0B | HK$3.31B | HK$3.02B | HK$2.72B |
| Net income | HK$9.11B | HK$9.20B | HK$2.27B | HK$1.71B | HK$2.23B |
| Free cash flow | HK$10.2B | HK$10.2B | HK$3.10B | HK$1.58B | HK$1.56B |
| Capital expenditure | HK$744M | HK$587M | HK$1.04B | HK$778M | HK$1.13B |
| Total debt | n/a | HK$2.92B | HK$3.78B | HK$5.33B | HK$5.07B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| 3SBio 1530.HK | $4.92B | -34% | +102% | 61% | 13.7× | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% |
| Cspc Pharma 1093.HK | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% |
| Shanghai Henlius Biotech 2696.HK | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% |
| Sbp 1177.HK | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1530.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.3% | +3.8% | 5th lowest of 21 |
| 6-month return | -33.8% | +2.4% | 2nd lowest of 21 |
| Distance from 52-week high | -57.1% | -23.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | +101.7% | +3.6% | highest of 15 |
| Operating margin | 60.6% | -23.4% | highest of 15 |
| Forward P/E | 13.7× | 37.3× | cheapest of 7 |
| ROIC minus cost of capital | +39.6 pp | -11.2 pp | highest of 14 |
| EV / EBITDA | 1.9× | n/a | — |
| Net debt / EBITDA | -1.5× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 13.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 13.7× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | n/a | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | n/a | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 40.9× | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | n/a | -6.4% | -10.0% |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 30.2× | 32.2% | +7.1% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 69.9× | 36.7% | +26.2% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $5.58B | -6% | +16% | 10% | 110.0× | 28.4% | +16.4% |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | n/a | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 33.6× | 3.2% | +12.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | n/a | n/a | n/a |